VSTM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
VSTM is NOT a good buy right now. Price is in a broader downtrend (bearish moving-average stack) and Intellectia has no AI Stock Picker or SwingMax buy signal to override that. While the stock is near support (~6.15) and options positioning leans modestly bullish, the highest-probability setup favors further choppiness/downside over the next month rather than an immediate, impatient-friendly upside move. I would stay out (hold/avoid new buys) unless it quickly reclaims the 6.49 pivot and holds above it.
Trend/levels: The moving averages are bearish (SMA_200 > SMA_20 > SMA_5), confirming a prevailing downtrend. Price (6.23 close; options snapshot price ~6.10) is sitting just above S1 support at 6.152; a clean break risks S2 at 5.944. To turn constructive, VSTM needs to reclaim the pivot 6.488, then push toward R1 6.824. Momentum: RSI(6) ~33.9 is weak and near oversold territory (not a clear reversal signal yet). MACD histogram is slightly positive (0.00876) but “positively contracting,” implying any bullish momentum is fading rather than accelerating. Pattern/odds: Similar-pattern stats suggest modest near-term bounce potential (next day/week slightly positive), but the next-month expectation is negative (-10.89%), aligning with the bearish trend.
Intellectia Proprietary Trading Signals: Intellectia Proprietary Trading Signals
Hedge funds are buying aggressively (reported +1120% QoQ buying amount), which can provide incremental support.
Commercial traction: Q3 2025 reflected the first full quarterly sales of the lead asset co-pack (~$11.2M per analyst note), showing product revenue is real.
Potential event catalyst: Upcoming earnings on 2026-02-10 (pre-market) can reset expectations if sales/updates beat.
Options market has a bullish lean (call-heavy open interest), which can amplify upside if news surprises positively.
Price trend is bearish (SMA structure), and the stock is hovering just above key support (~6.15). A break can trigger a fast move toward ~5.
Very high implied volatility signals uncertainty; if near-term catalysts disappoint, downside can be swift.
Company recently discontinued a development program (avutometinib/defactinib + sotorasib) and ended RAMP 203 (per analyst note). Even if not core to valuation, it reinforces pipeline/program risk.
Pattern-based outlook flags negative next-month bias (-10.89%), which is unfriendly for an impatient entry.
Latest quarter: 2025/Q3. Revenue rose to $11.24M (flat YoY in the snapshot, but consistent with the first full quarter of meaningful commercial sales referenced by analysts). Profitability worsened materially: net income was -$98.5M (loss widened ~311% YoY) and EPS was -$1.35 (worse by ~125% YoY). Gross margin declined to 82.57% (down ~17.43% YoY). Overall: early revenue base is forming, but losses/cash burn dynamics dominate near-term fundamentals.
Street view is still positive overall: Guggenheim reiterated Buy with a $14 PT (2025-12-30) and downplayed the discontinued NSCLC combo as not central to valuation; Mizuho reiterated Outperform with a $15 PT (2025-11-04), calling the selloff “overdone” despite Phase 3 enrollment additions and NCCN timing uncertainty. Wall Street pros: accelerating commercialization potential and multiple catalysts. Cons: execution/regulatory timing risk, ongoing large losses, and program/pipeline uncertainty. Politicians/congress: no recent congress trading data available; no notable insider trend (insiders neutral).
